Nocturia research: Current status and future perspectives

Neurourology and Urodynamics

Volumn 29, Issue 4, 2010, Pages 623-628

  Van Kerrebroeck, Philip E V ^a   Dmochowski, Roger ^b   FitzGerald, Mary P ^c   Hashim, Hashim ^d   Norgaard, Jens Peter ^e,f   Robinson, Dudley ^g   Weiss, Jeffrey P ^h  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VANDERBILT UNIVERSITY HOSPITAL   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d BRISTOL UROLOGICAL INSTITUTE   (United Kingdom)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f Ferring Pharmaceuticals AS   (Denmark)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

^h Downstate Health Sciences University   (United States)

Author keywords

LUTS; Nocturia; Overactive bladder; Research

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDIURETIC AGENT; CALCIUM ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESMOPRESSIN; DOXAZOSIN; FINASTERIDE; OXIDOREDUCTASE INHIBITOR; PROPIVERINE; SOLIFENACIN; TAMSULOSIN; TOLTERODINE;

ANTIDIURESIS; CHRONIC DISEASE; HEALTH; HUMAN; HYPONATREMIA; LIFESTYLE; LOWER URINARY TRACT SYMPTOM; MEDICAL RESEARCH; MICTURITION; MORBIDITY; MORTALITY; NOCTURIA; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; POLYURIA; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; SLEEP; SLEEP APNEA SYNDROME; SURVIVAL;

BIOMEDICAL RESEARCH; CHRONIC DISEASE; HUMANS; NOCTURIA; PROGNOSIS; TREATMENT OUTCOME;

EID: 77953556628     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20913     Document Type: Review

References (54)

1. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006;50:1306-1315
2. Yu HJ, Chen J, Lai MK, et al. High prevalence of voiding symptoms in Taiwanese women. Br J Urol 1998;82:520-523
3. Jolleys JV,DonovanJL,Nanchahal K, et al.Urinarysymptoms in thecommunity: How bothersome are they? Br J Urol 1994;74:551-555
4. Fiske J, ScarperoHM,XueX, et al. Degree of bother caused by nocturia inwomen. Neurourol Urodyn 2004;23:130-133
5. Chapple CR, Batista J, Berges R, et al. The impact of nocturia in patients with LUTS/BPH: Need for new recommendations. Eur Urol Suppl 2007;5:12-18
6. Asplund R. Nocturia: Consequences for sleep and daytime activities and associated risks. Eur Urol Suppl 2005;3:24-32.
7. Hernandez C, Estivill E, Prieto M, et al. Nocturia in Spanish patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Curr Med Res Opin 2008;24:1033-1038
8. Van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardisation of terminology in nocturia: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:179-183 (Pubitemid 34195212)
9. Hunter DJ, Berra-UnamunoA,Martin-Gordo A. Prevalence ofurinarysymptoms and other urological conditions in Spanish men 50 years old or older. J Urol 1996;155:1965-1970
10. Rembratt A, Norgaard JP, Andersson KE. Differences between nocturics and non-nocturics in voiding patterns: An analysis of frequency-volume charts from community-dwelling elderly. BJU Int 2003;91:45-50.
11. Bing MH, Moller LA, Jennum P, et al. Prevalence and bother of nocturia, and causes of sleep interruption in a Danish population of men and women aged 60-80 years. BJU Int 2006;98:599-604.
12. Tikkinen KA, Tammela TL, Huhtala H, et al. Is nocturia equally common among men and women? A population based study in Finland. J Urol 2006;175:596-600.
13. FitzGerald MP, Litman HJ, Link CL, et al. The association of nocturia with cardiac disease, diabetes, bodymass index, age and diuretic use: Results from the BACH survey. J Urol 2007;177:1385-1389
14. Lukacz ES, Whitcomb EL, Lawrence JM, et al. Urinary frequency in communitydwelling women: What is normal? Am J Obstet Gynecol 2009;200:552-557
15. Tikkinen KA, Johnson TM, Tammela TL, et al. Nocturia frequency, bother, and quality of life:Howoften is too often? A population-based study in Finland. Eur Urol 2010;57:488-496
16. Yu HJ, Chen FY, Huang PC, et al. Impact of nocturia on symptom-specific quality of life among community-dwelling adults aged 40 years and older. Urology 2006;67:713-718
17. Tikkinen KA, Auvinen A, Johnson TM, et al. A systematic evaluation of factors associated with nocturia-The population-based FINNO study. AmJ Epidemiol 2009;170:361-368
18. Yoshimura K, Terada N, Matsui Y, et al. Prevalence of and risk factors for nocturia: Analysis of a health screening program. Int J Urol 2004;11:282-287
19. Gourova LW, van de BC Spigt MG, et al. Predictive factors for nocturia in elderly men: A cross-sectional study in 21 general practices. BJU Int 2006;97:528-532
20. Asplund R. Mortality in the elderly in relation to nocturnal micturition. BJU Int 1999;84:297-301.
21. Bursztyn M, Jacob J, Stessman J. Usefulness of nocturia as a mortality risk factor for coronary heart disease among persons born in 1920 or 1921. Am J Cardiol 2006;98:1311-1315
22. Kujubu DA, Aboseif SR. Evaluation of nocturia in the elderly. Permanente J 2007;11:37-39
23. Weiss JP,Weinberg AC, Blaivas JG. Newaspects of the classification of nocturia. Curr Urol Rep 2008;9:362-367
24. Moriyama Y, Miwa K, Tanaka H, et al. Nocturia in men less than 50 years of age may be associated with obstructive sleep apnea syndrome. Urology 2008;71:1096-1098
25. Lowenstein L, Kenton K, Brubaker L, et al. The relationship between obstructive sleep apnea, nocturia, and daytime overactive bladder syndrome in women. Am J Obstet Gynecol 2008;198:598-605
26. Endeshaw YW, Johnson TM, Kutner MH, et al. Sleep-disordered breathing and nocturia in older adults. J AmGeriatr Soc 2004;52:957-960
27. Abrams P, Chapple C, Khoury S, et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009;181:1779-1787
28. Vavra I, Machova A, Holecek V, et al. Effect of a synthetic analogue of vasopressin in animals and in patients with diabetes insipidus. Lancet 1968;1:948-952
29. Hammer M, Vilhardt H. Peroral treatment of diabetes insipiduswith a polypeptide hormone analog, desmopressin. J Pharmacol Exp Ther 1985;234:754-760
30. Ziai F,Walter R, Rosenthal IM. Treatment of central diabetes insipidus in adults and children with desmopressin. Arch Intern Med 1978;138:1382-1385
31. Asplund R. Diuresis pattern, plasma vasopressin and blood pressure in healthy elderly persons with nocturia and nocturnal polyuria. Neth JMed2002;60:276-280
32. Hirayama A, Fujimoto K, Akiyama T, et al. Decrease in nocturnal urinary levels of arginine vasopressin in patients with nocturnal polyuria. Urology 2006;68:19-23.
33. Guilleminault C, Lin CM, Goncalves MA, et al. A prospective study of nocturia and the quality of life of elderly patients with obstructive sleep apnea or sleep onset insomnia. J Psychosom Res 2004;56:511-515
34. FitzGerald MP, Mulligan M, Parthasarathy S. Nocturic frequency is related to severity of obstructive sleep apnea, improves with continuous positive airways treatment. Am J Obstet Gynecol 2006;194:1399-1403
35. Kaye M. Aging, circadian weight change, and nocturia. Nephron Physiol 2008;109:11-18
36. Klingler HC, Heidler H, Madersbacher H, et al. Nocturia: An Austrian study on the multifactorial etiology of this symptom. Neurourol Urodyn 2009;28:427-431
37. Djavan B, Milania S, Daviesb J, et al. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: Preliminary results of a pilot study. Eur Urol Suppl 2005;4:61-68
38. Nitti VW,Dmochowski R, Appell RA, et al. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int 2006;97:1262-1266
39. Yamaguchi O, Marui E, Kakizaki H, et al. Randomized, double-blind, placeboand propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int 2007;100:579-587
40. Johnson TM,Burrows PK,Kusek JW, et al. The effect of doxazosin, finasterideand combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol 2007;178:2045-2050
41. Roehrborn CG, van KP, Nordling J. Safety and efficacy of alfuzosin 10mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A pooled analysis of three double-blind, placebocontrolled studies. BJU Int 2003;92:257-261
42. Yoshimura K, Ohara H, Ichioka K, et al. Nocturia and benign prostatic hyperplasia. Urology 2003;61:786-790
43. Lose G, Lalos O, Freeman RM, et al. Efficacy of desmopressin (Minirin) in the treatment of nocturia: A double-blind placebo-controlled study inwomen. Am J Obstet Gynecol 2003;189:1106-1113
44. Mattiasson A, Abrams P, Van Kerrebroeck P, et al. Efficacy of desmopressin in the treatment of nocturia: A double-blind placebo-controlled study in men. BJU Int 2002;89:855-862
45. van Kerrebroeck PE, Rezapour M, Cortesse A, et al. Desmopressin in the treatment of nocturia: A double-blind, placebo-controlled study. Eur Urol 2007;52:221-229
46. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 2004;172:1021-1025
47. Norgaard JP, Hashim H, Malmberg L, et al. Antidiuresis therapy: Mechanism of action and clinical implications. Neurourol Urodyn 2007;26:1008-1013
48. Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn 2006;25: 105-109
49. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-2398
50. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T,Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial. JAMA 2006;296:2319-2328
51. Nam S, Moon D, Kim J. Efficacy of desmopressin in treatment of adult nocturia. Korean J Urol 2004;45:49-55.
52. Abraham L, Hareendran A, Mills IW, et al. Development and validation of a quality-of-life measure for men with nocturia. Urology 2004;63:481-486
53. Chapple CR, Cardozo L, Steers WD, et al. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006;60:959-966
54. O'Leary MP, Roehrborn CG, Black L. Dutasteride significantly improves quality of life measures in patients with enlarged prostate. Prostate Cancer Prostatic Dis 2008;11:129-133